Literature DB >> 9790452

Effect of subcutaneous administration of octreotide on endogenous vasoactive systems and renal function in cirrhotic patients with ascites.

M Sàbat1, C Guarner, G Soriano, O Bulbena, M T Novella, J Ortiz, E Ricart, C Villanueva, J Rosello, J Rodríguez, J Balanzó.   

Abstract

Splanchnic and systemic arteriolar vasodilation plays an important role in ascites formation in cirrhosis. Octreotide produces splanchnic vasoconstriction, but the effects on systemic hemodynamics and renal function are controversial. This study evaluated the effect of subcutaneous octreotide administration on systemic hemodynamics, endogenous vasoactive systems, and renal function in cirrhotic patients with ascites. Twenty patients were included: 10 received octreotide 250 microg/12 hr subcutaneously (for five days), and 10 did not. No statistically significant changes were found in mean arterial pressure and cardiac rate. Octreotide induced a statistically significant decrease in plasma renin activity (P < 0.01), plasma aldosterone (P = 0.01) and plasma glucagon (P < 0.05). No significant variations were observed in other systemic vasoactive substances (nitric oxide and prostacyclin). Renal function was not modified in either group. In conclusion, in cirrhotic patients with ascites, subcutaneous octreotide administration decreases plasma glucagon, renin activity, and aldosterone without changing in systemic hemodynamics or renal function.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790452     DOI: 10.1023/a:1026698001921

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Acute changes in renal excretion of water and solute in patients with Laennec's cirrhosis, induced by the administration of the pressor amine, metaraminol.

Authors:  D L GORNEL; R G LANCESTREMERE; S PAPPER; L M LOWENSTEIN
Journal:  J Clin Invest       Date:  1962-03       Impact factor: 14.808

2.  Effect of octreotide on systemic, central, and splanchnic haemodynamics in cirrhosis.

Authors:  S Møller; K Brinch; J H Henriksen; U Becker
Journal:  J Hepatol       Date:  1997-05       Impact factor: 25.083

3.  SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action.

Authors:  W Bauer; U Briner; W Doepfner; R Haller; R Huguenin; P Marbach; T J Petcher
Journal:  Life Sci       Date:  1982-09-13       Impact factor: 5.037

4.  Enhancement of renal function by a long-acting somatostatin analogue in patients with decompensated cirrhosis.

Authors:  T Mountokalakis; N Kallivretakis; D Mayopoulou-Symvoulidou; G Karvountzis; G Tolis
Journal:  Nephrol Dial Transplant       Date:  1988       Impact factor: 5.992

Review 5.  Octreotide.

Authors:  S W Lamberts; A J van der Lely; W W de Herder; L J Hofland
Journal:  N Engl J Med       Date:  1996-01-25       Impact factor: 91.245

Review 6.  Peripheral arterial vasodilatation: determinant of functional spectrum of cirrhosis.

Authors:  R W Schrier; M Niederberger; A Weigert; P Ginès
Journal:  Semin Liver Dis       Date:  1994-02       Impact factor: 6.115

7.  Effect of a new somatostatin analogue SMS 201-995 (Sandostatin) on the renin-aldosterone axis.

Authors:  C Sieber; M Gnädinger; E Del Pozo; S Shaw; P Weidmann
Journal:  Clin Endocrinol (Oxf)       Date:  1988-01       Impact factor: 3.478

8.  Nitric oxide and arachidonate metabolism in ischemia-reperfusion associated with pancreas transplantation.

Authors:  G Hotter; D Closa; F Pi; N Prats; L Fernandez-Cruz; O Bulbena; E Gelpí; J Roselló-Catafau
Journal:  Transplantation       Date:  1995-02-15       Impact factor: 4.939

9.  Fasting and post-prandial splanchnic blood flow is reduced by a somatostatin analogue (octreotide) in man.

Authors:  A M Cooper; G D Braatvedt; M I Qamar; H Brown; D M Thomas; M Halliwell; A E Read; R J Corrall
Journal:  Clin Sci (Lond)       Date:  1991-08       Impact factor: 6.124

10.  Effects of somatostatin on renal function in cirrhosis.

Authors:  A Ginès; J M Salmerón; P Ginès; W Jiménez; J Saló; C Piera; J Clària; F Rivera; V Arroyo; J Rodés
Journal:  Gastroenterology       Date:  1992-12       Impact factor: 22.682

View more
  4 in total

1.  A somatostatin analog improves tilt table tolerance by decreasing splanchnic vascular conductance.

Authors:  S S Jarvis; J P Florian; M J Curren; J A Pawelczyk
Journal:  J Appl Physiol (1985)       Date:  2012-02-16

2.  48-hour hemodynamic effects of octreotide on postprandial splanchnic hyperemia in patients with liver cirrhosis and portal hypertension: double-blind, placebo-controlled study.

Authors:  D Ludwig; S Schädel; A Brüning; B Schiefer; E F Stange
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

3.  Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney.

Authors:  Edgar J Rolleman; Peter P M Kooij; Wouter W de Herder; Roelf Valkema; Eric P Krenning; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-02       Impact factor: 9.236

4.  Systemic hemodynamic and renal effects of midodrine and octreotide in cirrhotic patients with ascites.

Authors:  Georgios N Kalambokis; Epameinondas V Tsianos
Journal:  J Res Med Sci       Date:  2011-12       Impact factor: 1.852

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.